BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 5, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

4-22-cardiologs-platform.png

Study to evaluate benefit of Cardiologs’ AI-based tool in monitoring COVID-19 patients

April 22, 2020
By Meg Bryant
Paris-based health care startup Cardiologs Technologies SAS has launched a clinical study to assess the use of its artificial intelligence (AI) platform to remotely monitor cardiac safety in COVID-19 patients being treated with the malaria drug hydroxychloroquine. The study could help to detect and prevent serious cardiac effects of the drug.
Read More
Antibodies fighting coronavirus

Advamed’s Van Meter says COVID-19 antigen testing ramp-up on the short horizon

April 22, 2020
By Mark McCarty
The role of diagnostic and surveillance testing in the COVID-19 pandemic is unquestionably critical, but the volume and type of tests needed to bring the economy back online is complex. Susan Van Meter, director of Advamed Dx, said on an April 22 press briefing that while molecular and serological tests will continue to play a vital role, “we’re going to see millions of antigen tests available in the coming weeks,” a development that will prove crucial in efforts to restore normal economic activity.
Read More

Regulatory front for April 22, 2020

April 22, 2020
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Predictive Technology Group, SC Worx, Spectrum DNA.
Read More

Regulatory action for April 22, 2020

April 22, 2020
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Life Spine, Mobidiag, Seegene.
Read More

Other news to note for April 22, 2020

April 22, 2020
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aetion, Akili, Aptar, Avacta, Bioclinica, C3.ai, CDISC, Centerline Biomedical, Cole Medical, Cotiviti, Cytiva, Cytosmart Technologies, Entopsis, Federated Healthcare Supply Holdings, Florio, Genetics Institute of America, Healthverity, Horizon Discovery Group, Icecure Medical, Intraop Medical, Itamar Medical, Livanova, Maccabi Healthcare Services, Medtronic, Milestone Scientific, Mimedx Group, Mts Medical Technology, Nexa3D, Nuritas, Qualtrics, Quotient, Sonmol, Sono-Tek, Trividia Health, Vivalnk.
Read More
Pills under magnifying glass

COVID-19 underscores threat of counterfeit antibiotics, antimalarials

April 22, 2020
By Mari Serebrov
Recent seizures of fake medical products being marketed in the COVID-19 pandemic underscore the need to curb the growing international trade in counterfeit drugs that’s putting hundreds of thousands of lives at risk, the Organisation for Economic Cooperation and Development (OECD) warned this week.
Read More
2D nanoparticles

Nanobody startup Sysvax aims for COVID-19 cures with three approaches

April 22, 2020
By Elise Mak
BEIJING – Nanobody startup Sysvax Inc., with its R&D center in Beijing and manufacturing facilities in Zhongshan, is developing a recombinant protein vaccine and a nanobody therapeutic for COVID-19, while trying to extend the half-life of potential COVID-19 treatments with its expertise in this smallest possible antibody format.
Read More

Regulatory front for April 22, 2020

April 22, 2020
The latest global regulatory news, changes and updates affecting biopharma.
Read More

Regulatory actions for April 22, 2020

April 22, 2020
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Algernon, Biontech, Clarity, Janssen, Mallinckrodt, Novartis, Pfizer, Vitro.
Read More

Other news to note for April 22, 2020

April 22, 2020
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ablexis, Alkermes, Alpha Cognition, Anticancer, Applied Biomath, Asklepios, Avacta, Bayer Bonus Biogroup, Brainvectis, Caladrius, Cellphire, Cocrystal Pharma, Cormedix, Cyclica, Emergex Vaccines, Envisagenics, Etherna, Evotec, Frame, Gilead, Hoth, Immunic, Johnson & Johnson, Kalos, Kite, Linical, Northern Biologics, Nuritas, Oncology Venture, Onko-innate, Pharnext, Q Biomed, Sanofi, Som, Targovax, Valo, Wize, Wuxi, Zylö Therapeutics.
Read More
Previous 1 2 … 478 479 480 481 482 483 484 485 486 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4, 2026.
  • Brain and virus with chromosome

    CROI 2026: Neurodegeneration, the challenge of aging with HIV

    BioWorld
    Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
  • Depression concept with human, broken brain and heavy rain

    CROI 2026 highlights depression and cognitive vulnerability in HIV

    BioWorld
    The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Concept art for headache

    Slate Medicines launches with focus on headache disorders

    BioWorld Science
    Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing